Switch to:
Also traded in: Brazil, Germany, Mexico, Switzerland

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 0.04
TMO's Cash-to-Debt is ranked lower than
96% of the 235 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.33 vs. TMO: 0.04 )
Ranked among companies with meaningful Cash-to-Debt only.
TMO' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.04  Med: 0.41 Max: N/A
Current: 0.04
Equity-to-Asset 0.47
TMO's Equity-to-Asset is ranked lower than
71% of the 215 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.61 vs. TMO: 0.47 )
Ranked among companies with meaningful Equity-to-Asset only.
TMO' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.31  Med: 0.5 Max: 0.75
Current: 0.47
0.31
0.75
Interest Coverage 5.12
TMO's Interest Coverage is ranked lower than
77% of the 153 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 67.14 vs. TMO: 5.12 )
Ranked among companies with meaningful Interest Coverage only.
TMO' s Interest Coverage Range Over the Past 10 Years
Min: 5.12  Med: 6.56 Max: 14.24
Current: 5.12
5.12
14.24
Piotroski F-Score: 8
Altman Z-Score: 2.74
Beneish M-Score: -2.47
WACC vs ROIC
7.19%
7.18%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 9/10

vs
industry
vs
history
Operating Margin % 13.62
TMO's Operating Margin % is ranked higher than
78% of the 220 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.53 vs. TMO: 13.62 )
Ranked among companies with meaningful Operating Margin % only.
TMO' s Operating Margin % Range Over the Past 10 Years
Min: 10  Med: 11.78 Max: 14.82
Current: 13.62
10
14.82
Net Margin % 11.58
TMO's Net Margin % is ranked higher than
84% of the 219 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.44 vs. TMO: 11.58 )
Ranked among companies with meaningful Net Margin % only.
TMO' s Net Margin % Range Over the Past 10 Years
Min: 7.81  Med: 9.77 Max: 11.64
Current: 11.58
7.81
11.64
ROE % 10.13
TMO's ROE % is ranked higher than
68% of the 213 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.56 vs. TMO: 10.13 )
Ranked among companies with meaningful ROE % only.
TMO' s ROE % Range Over the Past 10 Years
Min: 5.36  Med: 7.8 Max: 10.13
Current: 10.13
5.36
10.13
ROA % 4.82
TMO's ROA % is ranked higher than
69% of the 236 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.39 vs. TMO: 4.82 )
Ranked among companies with meaningful ROA % only.
TMO' s ROA % Range Over the Past 10 Years
Min: 3.58  Med: 4.65 Max: 5.52
Current: 4.82
3.58
5.52
ROC (Joel Greenblatt) % 48.58
TMO's ROC (Joel Greenblatt) % is ranked higher than
80% of the 235 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.92 vs. TMO: 48.58 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
TMO' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 37.47  Med: 42.04 Max: 62.88
Current: 48.58
37.47
62.88
3-Year Revenue Growth Rate 8.70
TMO's 3-Year Revenue Growth Rate is ranked higher than
59% of the 159 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.40 vs. TMO: 8.70 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
TMO' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -12.9  Med: 7.3 Max: 18.7
Current: 8.7
-12.9
18.7
3-Year EBITDA Growth Rate 14.90
TMO's 3-Year EBITDA Growth Rate is ranked higher than
69% of the 144 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.60 vs. TMO: 14.90 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
TMO' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -30.1  Med: 14.9 Max: 40.9
Current: 14.9
-30.1
40.9
3-Year EPS without NRI Growth Rate 13.40
TMO's 3-Year EPS without NRI Growth Rate is ranked higher than
64% of the 129 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.00 vs. TMO: 13.40 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
TMO' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -43.5  Med: 14 Max: 74.6
Current: 13.4
-43.5
74.6
GuruFocus has detected 5 Warning Signs with Thermo Fisher Scientific Inc $TMO.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» TMO's 30-Y Financials

Financials (Next Earnings Date: 2017-07-26 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research    NAICS: 541380    SIC: 3826
Compare:NYSE:DHR, NYSE:Q, NYSE:A, NYSE:LH, NYSE:DGX, NAS:IDXX, OTCPK:SSMXY, OTCPK:ERFSF, OTCPK:BMXMF, NAS:QGEN, NYSE:PKI, NAS:INCR, NAS:DXCM, NYSE:BIO, NAS:ICLR, NAS:BRKR, NYSE:CRL, OTCPK:CZMWY, NAS:PRAH, NAS:PRXL » details
Traded in other countries:TMOS34.Brazil, TN8.Germany, TMO.Mexico, TFS.Switzerland,
Headquarter Location:USA
Thermo Fisher Scientific Inc offers analytical instruments, laboratory equipment, software, services, consumables, reagents, chemicals, and supplies to pharmaceutical and biotech companies, hospitals and clinical diagnostic labs.

Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments: analytical technologies (about 22% of sales after the FEI acquisition); specialty diagnostic products (18%); life science solutions (27% including Affymetrix); and lab products and services (37%).

Guru Investment Theses on Thermo Fisher Scientific Inc

Weitz Funds Comments on Thermo Fisher Scientific - Jan 26, 2017

Thermo Fisher Scientific (NYSE:TMO) provides analytical instruments, equipment, reagents and consumables, as well as software and services for research, analysis, discovery and diagnostics across most of the globe. Thermo is well-diversified by both product and end market, boasting strong defensible market positions and reputable brands. Roughly three quarters of the company’s revenues are recurring in nature (consumables and services), consistent with our preference for subscription-like cash flow streams. Its portfolio of businesses is characterized by stable pricing, relatively acyclical organic growth and consistent excess cash generation. We believe the life sciences tools and diagnostics industry is a “good neighborhood,” characterized by relatively high entry barriers, high customer switching costs and rational competitive behavior. Currency headwinds and investor rotation toward more cyclically- exposed areas of the industrial and healthcare sectors left Thermo’s stock largely unchanged the past 18 months while our estimate of business value grew nicely. We took advantage, initiating a position at, what we believe is, an attractive valuation.



  • From Weitz Investment Management's Value Fund 4th quarter 2016 commentary.


Check out Wallace Weitz latest stock trades

John Rogers Comments on Thermo Fisher Scientific Inc. - Jan 20, 2017

Also, scientific research supplier Thermo Fisher Scientific Inc. (NYSE:TMO) dropped –11.20% despite an earnings beat. The company reported earnings per share of $2.03 in late October, well ahead of the $1.97 consensus estimate; it also closed its acquisition of electron microscope maker FEI Company. Health care stocks were generally weak in November and December as investors rotated away from defensive stocks toward more aggressive ones. In our view, the company remains on the right track.

From John Rogers (Trades, Portfolio)' Ariel Appreciation Fund fourth quarter 2016 commentary.

Check out John Rogers latest stock trades

Top Ranked Articles about Thermo Fisher Scientific Inc

Tracking Portfolio Performance With Risk Analysis A deep look at key portfolio statistics measures
The “Five Criteria for Good Companies” model portfolio generated solid returns during the backtesting period from January 2006-2017, outperforming the Standard & Poor’s 500 exchange-traded fund benchmark in nine of the past 12 years. As of June 20, the portfolio generated a cumulative return of 261.72%, yielding an average excess return of about 5.72%. Read more...
Thermo Fisher Scientific Raises the Bar in Mass Spectrometry Innovation at ASMS 2017
Thermo Fisher Scientific to Acquire Patheon, a Leading Contract Development and Manufacturing Organization (CDMO)
Thermo Fisher Scientific to Host Analyst Meeting
New X-ray Machine Handles Heavy Products in Washdown Environments
Weitz Funds Comments on Thermo Fisher Scientific Guru stock highlight
Thermo Fisher Scientific (NYSE:TMO) provides analytical instruments, equipment, reagents and consumables, as well as software and services for research, analysis, discovery and diagnostics across most of the globe. Thermo is well-diversified by both product and end market, boasting strong defensible market positions and reputable brands. Roughly three quarters of the company’s revenues are recurring in nature (consumables and services), consistent with our preference for subscription-like cash flow streams. Its portfolio of businesses is characterized by stable pricing, relatively acyclical organic growth and consistent excess cash generation. We believe the life sciences tools and diagnostics industry is a “good neighborhood,” characterized by relatively high entry barriers, high customer switching costs and rational competitive behavior. Currency headwinds and investor rotation toward more cyclically- exposed areas of the industrial and healthcare sectors left Thermo’s stock largely unchanged the past 18 months while our estimate of business value grew nicely. We took advantage, initiating a position at, what we believe is, an attractive valuation. Read more...
John Rogers Comments on Thermo Fisher Scientific Inc. Guru stock highlight
Also, scientific research supplier Thermo Fisher Scientific Inc. (NYSE:TMO) dropped –11.20% despite an earnings beat. The company reported earnings per share of $2.03 in late October, well ahead of the $1.97 consensus estimate; it also closed its acquisition of electron microscope maker FEI Company. Health care stocks were generally weak in November and December as investors rotated away from defensive stocks toward more aggressive ones. In our view, the company remains on the right track. Read more...
5 Stocks Hit 52-Week High Prices Thermo Fisher and Goldman Sachs among companies with rising prices
According to GuruFocus' list of 52-week highs, these guru stocks have reached their historical high prices. Read more...

Ratios

vs
industry
vs
history
PE Ratio 31.73
TMO's PE Ratio is ranked higher than
59% of the 107 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 36.54 vs. TMO: 31.73 )
Ranked among companies with meaningful PE Ratio only.
TMO' s PE Ratio Range Over the Past 10 Years
Min: 12.67  Med: 26.51 Max: 62.79
Current: 31.73
12.67
62.79
Forward PE Ratio 18.83
TMO's Forward PE Ratio is ranked higher than
86% of the 36 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 24.57 vs. TMO: 18.83 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 31.67
TMO's PE Ratio without NRI is ranked higher than
60% of the 109 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 36.74 vs. TMO: 31.67 )
Ranked among companies with meaningful PE Ratio without NRI only.
TMO' s PE Ratio without NRI Range Over the Past 10 Years
Min: 13.48  Med: 26.55 Max: 62.07
Current: 31.67
13.48
62.07
Price-to-Owner-Earnings 25.98
TMO's Price-to-Owner-Earnings is ranked higher than
62% of the 68 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 32.56 vs. TMO: 25.98 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
TMO' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 9.21  Med: 18.88 Max: 107.6
Current: 25.98
9.21
107.6
PB Ratio 3.12
TMO's PB Ratio is ranked higher than
61% of the 210 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.94 vs. TMO: 3.12 )
Ranked among companies with meaningful PB Ratio only.
TMO' s PB Ratio Range Over the Past 10 Years
Min: 0.83  Med: 1.6 Max: 3.17
Current: 3.12
0.83
3.17
PS Ratio 3.69
TMO's PS Ratio is ranked higher than
50% of the 213 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.68 vs. TMO: 3.69 )
Ranked among companies with meaningful PS Ratio only.
TMO' s PS Ratio Range Over the Past 10 Years
Min: 1.24  Med: 2.52 Max: 3.73
Current: 3.69
1.24
3.73
Price-to-Free-Cash-Flow 24.96
TMO's Price-to-Free-Cash-Flow is ranked higher than
51% of the 79 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 25.07 vs. TMO: 24.96 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
TMO' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 10.2  Med: 19.93 Max: 34.98
Current: 24.96
10.2
34.98
Price-to-Operating-Cash-Flow 21.67
TMO's Price-to-Operating-Cash-Flow is ranked lower than
53% of the 91 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 19.63 vs. TMO: 21.67 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
TMO' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 8.72  Med: 17.12 Max: 28.82
Current: 21.67
8.72
28.82
EV-to-EBIT 32.41
TMO's EV-to-EBIT is ranked lower than
63% of the 115 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. TMO: 32.41 )
Ranked among companies with meaningful EV-to-EBIT only.
TMO' s EV-to-EBIT Range Over the Past 10 Years
Min: 10.8  Med: 23.9 Max: 86.3
Current: 32.41
10.8
86.3
EV-to-EBITDA 19.12
TMO's EV-to-EBITDA is ranked higher than
52% of the 127 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 19.45 vs. TMO: 19.12 )
Ranked among companies with meaningful EV-to-EBITDA only.
TMO' s EV-to-EBITDA Range Over the Past 10 Years
Min: 6.6  Med: 14.5 Max: 44.9
Current: 19.12
6.6
44.9
PEG Ratio 2.16
TMO's PEG Ratio is ranked higher than
69% of the 49 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.17 vs. TMO: 2.16 )
Ranked among companies with meaningful PEG Ratio only.
TMO' s PEG Ratio Range Over the Past 10 Years
Min: 0.51  Med: 1.66 Max: 2.95
Current: 2.16
0.51
2.95
Shiller PE Ratio 47.26
TMO's Shiller PE Ratio is ranked higher than
52% of the 31 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 47.43 vs. TMO: 47.26 )
Ranked among companies with meaningful Shiller PE Ratio only.
TMO' s Shiller PE Ratio Range Over the Past 10 Years
Min: 20.78  Med: 41.55 Max: 63.12
Current: 47.26
20.78
63.12
Current Ratio 1.37
TMO's Current Ratio is ranked lower than
80% of the 235 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.73 vs. TMO: 1.37 )
Ranked among companies with meaningful Current Ratio only.
TMO' s Current Ratio Range Over the Past 10 Years
Min: 0.9  Med: 2.42 Max: 3.83
Current: 1.37
0.9
3.83
Quick Ratio 0.93
TMO's Quick Ratio is ranked lower than
83% of the 235 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.17 vs. TMO: 0.93 )
Ranked among companies with meaningful Quick Ratio only.
TMO' s Quick Ratio Range Over the Past 10 Years
Min: 0.61  Med: 1.85 Max: 3.4
Current: 0.93
0.61
3.4
Days Inventory 80.43
TMO's Days Inventory is ranked higher than
52% of the 186 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 82.10 vs. TMO: 80.43 )
Ranked among companies with meaningful Days Inventory only.
TMO' s Days Inventory Range Over the Past 10 Years
Min: 65.13  Med: 69.62 Max: 80.43
Current: 80.43
65.13
80.43
Days Sales Outstanding 60.30
TMO's Days Sales Outstanding is ranked higher than
50% of the 188 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 60.30 vs. TMO: 60.30 )
Ranked among companies with meaningful Days Sales Outstanding only.
TMO' s Days Sales Outstanding Range Over the Past 10 Years
Min: 50.89  Med: 53.81 Max: 60.89
Current: 60.3
50.89
60.89
Days Payable 37.11
TMO's Days Payable is ranked lower than
69% of the 183 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 59.24 vs. TMO: 37.11 )
Ranked among companies with meaningful Days Payable only.
TMO' s Days Payable Range Over the Past 10 Years
Min: 31.3  Med: 32.52 Max: 41.58
Current: 37.11
31.3
41.58

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 0.35
TMO's Dividend Yield % is ranked lower than
88% of the 98 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.90 vs. TMO: 0.35 )
Ranked among companies with meaningful Dividend Yield % only.
TMO' s Dividend Yield % Range Over the Past 10 Years
Min: 0.22  Med: 0.47 Max: 0.86
Current: 0.35
0.22
0.86
Dividend Payout Ratio 0.11
TMO's Dividend Payout Ratio is ranked higher than
98% of the 64 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.34 vs. TMO: 0.11 )
Ranked among companies with meaningful Dividend Payout Ratio only.
TMO' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.11  Med: 0.13 Max: 0.17
Current: 0.11
0.11
0.17
Forward Dividend Yield % 0.35
TMO's Forward Dividend Yield % is ranked lower than
90% of the 96 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.91 vs. TMO: 0.35 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 0.34
TMO's 5-Year Yield-on-Cost % is ranked lower than
90% of the 124 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.42 vs. TMO: 0.34 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
TMO' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.22  Med: 0.47 Max: 0.86
Current: 0.34
0.22
0.86
3-Year Average Share Buyback Ratio -2.80
TMO's 3-Year Average Share Buyback Ratio is ranked higher than
65% of the 149 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.50 vs. TMO: -2.80 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
TMO' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -37.3  Med: -3.8 Max: 4.4
Current: -2.8
-37.3
4.4

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 1.53
TMO's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
74% of the 72 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.41 vs. TMO: 1.53 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
TMO' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.59  Med: 1.57 Max: 43.11
Current: 1.53
0.59
43.11
Price-to-Intrinsic-Value-DCF (Earnings Based) 1.38
TMO's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked higher than
78% of the 18 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.07 vs. TMO: 1.38 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
N/A
Price-to-Median-PS-Value 1.46
TMO's Price-to-Median-PS-Value is ranked lower than
75% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.03 vs. TMO: 1.46 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
TMO' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.23  Med: 0.74 Max: 1.46
Current: 1.46
0.23
1.46
Price-to-Peter-Lynch-Fair-Value 2.34
TMO's Price-to-Peter-Lynch-Fair-Value is ranked higher than
53% of the 30 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.51 vs. TMO: 2.34 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
TMO' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.59  Med: 1.62 Max: 14.2
Current: 2.34
0.59
14.2
Earnings Yield (Greenblatt) % 3.09
TMO's Earnings Yield (Greenblatt) % is ranked higher than
70% of the 238 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.52 vs. TMO: 3.09 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
TMO' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 1.2  Med: 4.2 Max: 9.3
Current: 3.09
1.2
9.3
Forward Rate of Return (Yacktman) % 16.62
TMO's Forward Rate of Return (Yacktman) % is ranked higher than
78% of the 65 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.56 vs. TMO: 16.62 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
TMO' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 13.6  Med: 20.9 Max: 33.9
Current: 16.62
13.6
33.9

More Statistics

Revenue (TTM) (Mil) $18,744.30
EPS (TTM) $ 5.48
Beta0.98
Short Percentage of Float0.84%
52-Week Range $139.07 - 176.92
Shares Outstanding (Mil)391.22

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 19,632 21,035 21,177
EPS ($) 9.20 10.26 11.05
EPS without NRI ($) 9.20 10.26 11.05
EPS Growth Rate
(Future 3Y To 5Y Estimate)
10.59%
Dividends per Share ($) 0.61 0.63 0.69
» More Articles for TMO

Headlines

Articles On GuruFocus.com
GAMCO Analyst: Is VMware a Compelling Investment Idea in Data Infrastructure? Jun 26 2017 
Gabelli TV: 2017 American Water Works Annual Conference Recap Jun 26 2017 
Monthly Dividend Stocks to Pay Your Bills Jun 26 2017 
The Rubicon Project: Who Is Selling and Why It's Creating a Bargain Price Jun 26 2017 
Sports, Stocks and the Magic Quadrants Jun 26 2017 
GMO Global Equity Insights - Whiplash: On Value, Growth and Ignoring the Fundamentals Jun 26 2017 
Dan Loeb's Third Point Letter on $3.5 Billion Nestle Purchase, Plans to Sells L'Oreal Jun 26 2017 
Canaries in the Coal Mine – What to Watch as Stocks Continue to Make New Highs Jun 26 2017 
A Look at Darden Valuation Jun 26 2017 
Is Dollar Tree Oversold With Potential Cuts to SNAP? Jun 26 2017 

More From Other Websites
Thermo Fisher Gets FDA's PMA for Oncomine Dx Target Test Jun 27 2017
Featured Company News - Thermo Fisher's Companion Diagnostic Test to Screen Multiple Non-Small Cell... Jun 26 2017
Why Hold Strategy is Apt for Thermo Fisher (TMO) Stock Now Jun 22 2017
ETFs with exposure to Thermo Fisher Scientific, Inc. : June 20, 2017 Jun 20 2017
Thermo Fisher Scientific, Inc. :TMO-US: Earnings Analysis: Q1, 2017 By the Numbers : June 19, 2017 Jun 19 2017
How Stryker’s Margins Are Driven by Its CTG Program Jun 19 2017
Thermo Fisher Scientific, Inc. : TMO-US: Dividend Analysis : June 15th, 2017 (record date) : By the... Jun 15 2017
PerkinElmer Among Targets Fitting Thermo Fisher's M&A Criteria Jun 13 2017
Earnings up at Patheon ahead of acquisition by Thermo Fisher Jun 09 2017
Behind Thermo Fisher’s Recent Stock Performance Jun 05 2017
Thermo Fisher Scientific Raises the Bar in Mass Spectrometry Innovation at ASMS 2017 Jun 05 2017
Thermo Fisher on the Street: Inside the Analyst Recommendations Jun 05 2017
Understanding Thermo Fisher’s Capital Deployment Strategy Jun 02 2017
What Does Thermo Fisher Want in the Clinical Mass Spectrometry Business? Jun 02 2017
Inside Thermo Fisher’s Key Partnerships in Diagnostics Jun 02 2017
Understanding Thermo Fisher’s Growth Strategy Jun 01 2017
How Long Can Thermo Fisher Scientific’s Asia-Pacific Growth Momentum Last? Jun 01 2017
Thermo Fisher’s Next Big Deal in the Medical Device Industry Jun 01 2017
Here’s What Keeps Boosting Thermo Fisher’s Growth May 31 2017
3 Top Gene-Sequencing Stocks Poised for Solid Growth May 31 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}